NEW YORK, April 17 – Luminex has licensed its LabMap technology to ARUP Laboratories, a national specialty diagnostic reference laboratory, the company said Tuesday.

Under the agreement, ARUP will use Luminex’s technology to develop clinical laboratory assays for antibodies to common disease agents, such as Streptococcus pneumoniae  and mitogens. Luminex will receive royalties on the sale of these diagnostic tests. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.